Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3

June 11, 2026 07:00 AM EDT R&D Takeda's plaque pso­ri­a­sis pill beats Bris­tol My­er­s' So­tyk­tu in Phase 3 Max Gelman Senior Editor Take­da’s $4 bil­lion bet on an oral plaque pso­ri­a­sis drug has paid off again, as the com­pa­ny re­port­ed the pill beat Bris­tol My­ers Squibb’s So­tyk­tu … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER